

Bulletin from the Annual General Meeting of Devyser Diagnostics AB (publ) held on 14 May 2025

The Annual General Meeting of Devyser Diagnostics AB (publ) ("Devyser" or the "Company") was held on Tuesday, 14 May 2025 at Bränningevägen 12, 120 54 Årsta. The main resolutions passed at the Meeting include the following.

Income statement and balance sheet as well as consolidated income statement and balance sheet

It was resolved to adopt the income statement and balance sheet, as well as the consolidated income statement and balance sheet, included in the Company's annual report.

It was resolved, pursuant to the proposal from the Board of Directors, that the total funds of SEK 270,247,858 available to the Annual General Meeting should be carried forward.

The Board of Directors and Auditor

It was resolved to discharge the members of the Board of Directors and the Chief Executive Officer from liability in relation to their management of the Company's operations during the period covered by the audit report.

It was resolved that the number of members of the Board of Directors appointed by the Annual General Meeting shall be six. It was resolved that the number of auditors should continue to be one.

For the period until the end of the next Annual General Meeting, Mia Arnhult, Fredrik Dahl, Pia Gideon and Thomas Eklund were re-elected as members of the Board of Directors. Isabelle Ducellier and Olof Ericsson were elected as new members of the Board of Directors for the same period.

For the period until the end of the next Annual General Meeting, Mia Arnhult was re-elected as Chairman of the Board of Directors. It was resolved to, for the period until the end of the next Annual General Meeting, re-elect the auditing firm Öhrlings PricewaterhouseCoopers AB (PwC) as auditor. It was noted that the authorized public accountant Magnus Lagerberg would be auditor-in-charge.

Fees to the Board of Directors and the Auditor

It was resolved to approve the fees to the Board of Directors as proposed by the Nomination Committee, entailing a fee of SEK 420,000 to the Chairman and a fee of SEK 200,000 to each of the other members of the Board of Directors, amounting to a total fee of SEK 1,420,000. The Annual General Meeting further resolved that a member of the Board of Directors who is also the Chairman of the Audit Committee shall be entitled to an additional fee of SEK 65,000, and a member of the Board of Directors who is also a member of the Audit Committee shall be entitled to an additional fee of SEK 25,000.

The Annual General Meeting approved the Nomination Committee's proposal that the auditor's fee shall be paid according to an approved invoice.

Remuneration guidelines for senior management

It was resolved to approve the Board of Directors' proposed remuneration guidelines for senior management.

Authorization for the Board of Directors to resolve upon share issues

It was resolved, in accordance with the Board of Director's proposal, to authorize the Board to resolve upon issues of shares and other financial instruments – with deviation from the shareholders' preferential rights – to facilitate financing of the operations, corporate acquisitions and broadening the shareholder base.

Employee stock option program and issue of warrants

It was noted that the Board of Directors had decided to withdraw the proposal to establish an employee stock option program following discussions with some of the Company's shareholders, through which it had been concluded that the proposal would not obtain the required majority. Thus, no proposal was presented, and no resolution could be adopted.

For more information, please contact:

Fredrik Dahl, interim CEO

Email: ir@devyser.com

Telephone: +46 8 562 158 50

Sabina Berlin, CFO

Email: ir@devyser.com

Telephone: +46 8 562 158 50



PRESS RELEASE
14 May 2025 12:30:00 CEST

About Devyser

Devyser develops, manufactures and sells diagnostic solutions and analysis services to clinical laboratories in more than 65 countries. Our products are used for advanced genetic testing in the hereditary disease, oncology and transplant fields, to enable targeted cancer treatment, the diagnosis of a large number of genetic diseases, and transplant patient follow-up. Devyser's products, and unique, patented solution requiring only one test tube, simplify genetic testing processes, improve sample throughput, minimize hands-on time and deliver rapid results. Our goal is for every patient to receive a correct diagnosis in the shortest possible time. Sustainability is a central part of our business and an important prerequisite for long term value creation.

Devyser was founded in 2004 and is based in Stockholm, Sweden with eight in-house sales offices in Europe and the US. The company also runs Devyser Genomic Laboratories, a CLIA certified laboratory in Atlanta, US. In 2022, Devyser's quality management system was certified according to the IVDR and a number of the company's products have since been certified according to the IVDR.

Devyser's shares are listed on the Nasdaq First North Premier Growth Market Stockholm (ticker: DVYSR). The company's Certified Adviser is Redeye AB.

For more information, visit www.devyser.com.